DUPIXENT reduced the need for sinus surgery
and/or systemic corticosteroid use by 76%

83^%

REDUCTION IN THE NEED
FOR SINUS SURGERY

vs placebo through
Week 52 (HR: 0.17
[95% CI: 0.07, 0.46])¹

74^%

REDUCTION IN THE
NEED FOR SYSTEMIC CORTICOSTEROID USE

vs placebo through
Week 52 (HR: 0.26
[95% CI: 0.18, 0.38])¹

^aIndividually, SCS reduction and need for sinus surgery were not multiplicity-adjusted endpoints.²

^bIn SINUS-24 and SINUS-52, DUPIXENT 300 mg Q2W + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).¹

CI, confidence interval; HR, hazard ratio; INCS, intranasal corticosteroid; SCS, systemic corticosteroid.